Table 1. Serum 25(OH)D levels in colorectal cancer patients in relation to clinical and pathological characteristics.
| serum 25(OH)D, nmol/L, median (IQR) | p value | |
|---|---|---|
| Gender | ||
| Male (n = 58) | 52.7 (38.3–69.5) | 0.204 |
| Female (n = 59) | 47.6 (37.7–58.5) | |
| Age | ||
| <65 years (n = 43) | 50.2 (37.7–60.8) | 0.746 |
| ≥65 years (n = 74) | 48.6 (38.9–66.5) | |
| Body mass index | ||
| <25 (n = 47) | 50.4 (37.4–67.0) | 0.0032 |
| 25–30 (n = 46) | 52.7 (45.2–70.5) | |
| >30 (n = 22) | 39.8 (31.7–46.4) | |
| Time of operation | ||
| Winter (Dec-Feb) (n = 21) | 43.6 (30.2–58.1) | 0.012 |
| Spring (Mar-May) (n = 34) | 42.3 (34.2–54.6) | |
| Summer (Jun-Aug) (n = 41) | 53.6 (46.1–70.7) | |
| Autumn (Sep-Nov) (n = 21) | 52.6 (45.1–63.9) | |
| Tumor location | ||
| Proximal colon (n = 49) | 46.1 (34.9–54.5) | 0.116 |
| Distal colon (n = 28) | 55.9 (43.9–66.3) | |
| Rectum (n = 40) | 51.6 (39.7–71.0) | |
| Morphology | ||
| Conventional (n = 89) | 52.6 (40.5–65.1) | 0.029 |
| Serrated (n = 28) | 42.9 (31.0–52.7) | |
| TNM Stage | ||
| Stage I (n = 19) | 60.8 (44.7–75.3) | 0.420A |
| Stage II (n = 46) | 48.1 (37.4–56.0) | |
| Stage III (n = 32) | 48.1 (38.9–71.7) | |
| Stage IV (n = 18) | 49.8 (31.0–60.3) | |
| Depth of invasion | ||
| T1 (n = 5) | 45.3 (38.3–78.7) | 0.267 |
| T2 (n = 19) | 60.8 (41.3–76.9) | |
| T3 (n = 83) | 47.9 (37.1–57.8) | |
| T4 (n = 9) | 60.2 (41.1–69.2) | |
| Nodal metastasis | ||
| N0 (n = 69) | 50.0 (38.7–64.2) | 0.939 |
| N1 (n = 27) | 48.8 (35.8–71.3) | |
| N2 (n = 19) | 50.6 (41.3–59.5) | |
| Distant metastasis | ||
| M0 (n = 98) | 49.0 (39.1–66.5) | 0.513 |
| M1 (n = 18) | 49.8 (31.0–60.3) | |
| WHO Grade 1–3 | ||
| Grade 1 (n = 16) | 56.0 (37.0–71.0) | 0.205 |
| Grade 2 (n = 86) | 50.3 (39.1–62.1) | |
| Grade 3 (n = 14) | 43.1 (33.6–55.8) | |
| Mismatch repair (MMR) enzyme status | ||
| MMR-deficient (n = 11) | 35.3 (32.0–45.5) | 0.018 |
| MMR-proficient (n = 105) | 50.4 (39.9–66.2) | |
| BRAF or KRAS mutation | ||
| BRAF mutation (n = 12) | 42.7 (35.3–62.2) | 0.512 |
| KRAS mutation (n = 30) | 47.2 (37.1–67.4) | |
| No BRAF nor KRAS mutation (n = 74) | 52.6 (39.7–64.1) | |
| Modified Glasgow Prognostic score (mGPS) | ||
| 0 (n = 91) | 50.6 (39.2–69.4) | 0.050 |
| 1–2 (n = 26) | 46.1 (33.8–53.9) | |
Abbreviations: IQR: interquartile range. The p-values are for Mann-Whitney or Kruskal-Wallis test.
AStage I vs. II-IV: p = 0.119.